Purchase Order 36C26126P0405

Edwards Lifesciences LLC received a $32.5K firm fixed-price purchase order from the Department of Veterans Affairs' Veterans Integrated Service Network 21 (VISN 21) for transcatheter aortic valve replacement (TAVR) surgical implants and related prosthetics restocking. The contract, awarded on February 9, 2026, carries an ultimate completion date of May 8, 2026, with performance taking place at the VA Palo Alto Health Care System in San Francisco, California. No set-aside designation was utilized for this procurement. This purchase order represents a routine resupply transaction under Edwards Lifesciences' existing framework relationship with VISN 21, which operates under a five-year, $6.5M indefinite delivery contract for surgical implant consignment services effective through December 31, 2030.

Edwards Lifesciences LLC, a self-certified small disadvantaged business and subsidiary of Edwards Lifesciences Corporation, specializes in advanced cardiovascular medical devices and has emerged as the primary supplier of specialized cardiac implants to the VA healthcare system. The company's TAVR systems and SAPIEN transcatheter heart valves with RESILIA tissue technology are critical components of the VA's cardiac surgical programs supporting veteran patient outcomes. As a sole-source supplier of these proprietary technologies, Edwards Lifesciences has received over 200 prime federal contract awards predominantly from the VA across multiple service networks since 2025, complemented by additional contracts from the Defense Health Agency.